New transplant approach aims to tame immune disorders without full chemo

NCT ID NCT04528355

Recruiting now Disease control Sponsor: Paul Szabolcs Source: ClinicalTrials.gov ↗

First seen Jan 13, 2026 · Last updated May 17, 2026 · Updated 13 times

Summary

This study looks at how well a gentler chemotherapy regimen works before stem cell transplants in people with non-cancerous blood or immune diseases. Researchers will track survival, graft-versus-host disease, and how well donor cells take hold. The goal is to improve outcomes for patients aged 2 months to 60 years with conditions like primary immune deficiencies or inherited anemias.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL BONE MARROW FAILURE SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UPMC Children's Hospital of Pittsburgh
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States

Contact

Contact

Contact

Contact

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CONGENITAL BONE MARROW FAILURE SYNDROMES HEREDITARY ANEMIAS INFLAMMATORY CONDITIONS INHERITED METABOLIC DISORDERS (IMD) PRIMARY IMMUNODEFICIENCY (PID)